Economic analysis of Radiation Therapy Oncology Group 97-14: Multiple versus single fraction radiation treatment of patients with bone metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 4, 2009, Pages 423-428

  Konski, Andre ^a,h   James, Jennifer ^b   Hartsell, William ^c   Leibenhaut, Mark H ^d   Janjan, Nora ^e   Curran, Walter ^f   Roach, Mack ^g   Watkins Bruner, Deborah ^g  

^a FOX CHASE CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c Radiological Associates of Sacramento Medical Group Inc   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastases; Cost effectiveness; Radiation

Indexed keywords

ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HUMAN; MALE; PAIN; QUALITY ADJUSTED LIFE YEAR; RADIATION DOSE; RETREATMENT; TREATMENT RESPONSE;

BONE NEOPLASMS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOSE FRACTIONATION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; PAIN MEASUREMENT; PALLIATIVE CARE; QUALITY-ADJUSTED LIFE YEARS; RADIATION ONCOLOGY; RADIOTHERAPY; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; UNITED STATES;

EID: 69349098640     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31818da9f7     Document Type: Article

References (12)

1. Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52:101-109. (Pubitemid 29461077)
2. Nielsen OS, Bentzen SM, Sandberg E, et al. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol. 1998;47:233-240. (Pubitemid 28293643)
3. Niewald M, Tkocz HJ, Abel U, et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int J Radiat Oncol Biol Phys. 1996;36:1085-1089. (Pubitemid 27014494)
4. Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6:247-255. (Pubitemid 16026730)
5. Rasmusson B, Vejborg I, Jensen AB, et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol. 1995;34:179-184.
6. Hartsell WF, Scott C, Bruner DW, et al. Phase III randomized trial of 8 Gy in 1 fraction vs. 30 Gy in 10 fractions for palliation of painful bone metastases: preliminary results of RTOG 97-14. Int J Radiat Oncol Biol Phys. 2003;57:S124.
7. Konski A, Desilvio M, Hartsell W, et al. Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14. Int J Radiat Oncol Biol Phys. 2006;66:229-233. (Pubitemid 44175649)
8. van den Hout WB, van der Linden YM, Steenland E, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: costutility analysis based on a randomized trial. J Natl Cancer Inst. 2003;95:222-229. (Pubitemid 36240635)
9. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1373-1378. (Pubitemid 39601854)
10. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97:798-804. (Pubitemid 40909122)
11. Johnston K, Gray A, Moher M, et al. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care. 2003;19:476-489. (Pubitemid 38649116)
12. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. (Pubitemid 46972777)